In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Pfizer released positive top line results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide). 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Applications for AVT03, a proposed biosimilar candidate to the Prolia and Xgeva (denosumab), submitted by Germany’s STADA Arzneimittel. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Bayer has entered into a collaboration with MOMA Therapeutics to develop a small molecule oncology program using the latter’s proprietary KNOMATIC platform. 9 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
Germany’s Eckert & Ziegler, a specialist in radioisotopes for medical, scientific and industrial applications, has announced a global clinical supply agreement with GlyTherix, an Australian targeted radiotherapy firm specializing in developing antibody radiopharmaceuticals for solid tumors. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
PharmaMar has entered into an exclusive license and commercialization agreement with TTY Biopharm to market and distribute the drug candidate Aplidin (plitidepsin) in Taiwan. 23 July 2015
The European Commission has approved US pharma giant Merck & Co’s Keytruda (pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of advanced (unresectable or metastatic) melanoma in adults. 23 July 2015
Danish biotech company Genmab has submitted a supplemental Biologics License Application to the US Food and Drug Administration for Arzerra (ofatumumab) as a maintenance therapy of patients with relapsed chronic lymphocytic leukemia. 23 July 2015
Japanese drug major Eisai said its activity in the UK may be impacted by the substantial concessions to the NHS in a bid to continue the inclusion of its breast cancer treatment Halaven (eribulin) in the Cancer Drugs Fund (CDF). 23 July 2015
AstraZeneca today announced that the Phase III SUMIT study of selumetinib in combination with dacarbazine for the treatment of patients with metastatic uveal melanoma did not meet its primary endpoint of progression free survival. 22 July 2015
The National Institute for Health and Care Excellence (NICE) has issued final guidance for Vargatef (nintedanib) from German family-owned pharma major Boehringer Ingelheim. 22 July 2015
The European commission has approved Opdivo (nivolumab) from Bristol-Myers Squibb for previously-treated advanced squamous non-small cell lung cancer. 21 July 2015
US pharma company Exelixis has announced positive top-line results from the primary analysis of its Phase III pivotal trial comparing cabozantinib to everolimus in patients with metastatic renal cell carcinoma (RCC). 21 July 2015
US biotech firm Agenus has acquired rights to antibodies targeting Carcinoembryonic Antigen Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein expressed on T cell and NK cell lymphocytes, from Diatheva, an Italian biotech company controlled by SOL SpA. 20 July 2015
Chugai Pharmaceutical has entered into license agreement with privately-held Kowa Company for peretinoin (development code: NIK-333), for which Kowa is currently conducting clinical development for prevention of recurrence of hepatocellular carcinoma. 17 July 2015
A made-in-Singapore cancer drug has advanced into clinical trials, charting a milestone in Singapore’s biomedical sciences initiative that will go towards improving the lives of cancer patients in Singapore, and worldwide. 16 July 2015
CANbridge Life Sciences has entered into an exclusive license agreement with privately-held German immuno-oncology company, Apogenix to develop, manufacture and commercialize the latter’s lead product, APG101, in glioblastoma multiforme in China, Macao, and Hong Kong. 15 July 2015
USA-based Epirus Biopharmaceuticals and Polpharma Group, Poland’s largest drugmaker, have signed a multi-product, multi-region profit-sharing collaboration for select Epirus biosimilars. 14 July 2015
Swiss drug major Roche saw its shares edge up 1.6% on Monday, after it released encouraging results with its investigational drug atezolizumab. 14 July 2015
The Delhi High Court of India has upheld the patent of US pharma major Bristol Myers Squibs for Sprycel (dasatinib), reports The Economic Times of India. 14 July 2015